Mitochondria and Metabolism in Right Heart Failure by Bruns, Danielle R. & Walker, Lori A.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 1
Mitochondria and Metabolism in Right Heart Failure
Danielle R. Bruns and Lori A. Walker
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.70450
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Danielle R. Bruns and Lori A. Walker
Additional information is available at the end of the chapter
Abstract
Heart failure (HF) is a clinically complex and heterogenous disease characterized by an 
inability of the heart to pump sufficient blood to the periphery. As such, it has historically 
been thought of and studied as a disease of the left ventricle (LV). While LV failure is the 
most common form of HF, it is the ability of the right heart to function that predicts sur-
vival in many clinical settings. Extrapolation of mechanisms of left HF to the right ven-
tricle (RV) has yet to prove fruitful in identification of therapeutic approaches, in large 
part due to a lack of basic mechanistic understanding of the RV which is embryologically, 
anatomically, and physiologically distinct from the LV. The failing LV is characterized 
by mitochondrial dysfunction and a metabolic switch, both of which contribute to an 
energetically starved heart with poor contractile ability. These mechanisms, however, are 
far less described in the failing RV. The purpose of this chapter is to present the current 
literature examining the role of mitochondria and metabolism in the healthy right heart, 
treatments to target deficits in the failing RV, and to identify knowledge gaps for future 
research in this clinically important area.
Keywords: heart failure, right ventricle, mitochondria, metabolism, ventricular dysfunction, 
pulmonary hypertension
1. Introduction
Cardiovascular disease is the leading cause of death worldwide, of which heart failure (HF) 
constitutes a growing public health concern. In the United States alone, close to 6 million 
individuals currently suffer from HF, accounting for nearly one of out every nine deaths [1]. 
Morbidity and mortality from HF are high, with 50% mortality within the first 5 years of diag-
nosis. HF is also a financial burden on the healthcare system, with direct costs estimated at 
$32 billion per year in the United States [2], roughly 2–3% of total global healthcare spending.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
While HF constitutes a complex syndrome of diseases, it generally refers to the inability of the 
heart to pump sufficient blood to the periphery. As such, historically HF has been studied as a 
disease of the left ventricle (LV), and most treatments for HF are designed to improve function 
of the failing LV. Hallmarks of current HF therapies include neurohormonal targets, vasodila-
tors, and/or reducing heart rate- all of which should reduce myocardial oxygen consumption 
and workload and rebalance energy supply and demand in the heart. However, these thera-
peutic approaches are largely based on symptom management and have not significantly 
changed the clinical course of the disease, as the staggering HF morbidity and mortality sta-
tistics have remained largely the same over the past 15 years [3]. These data suggest new 
therapeutic strategies are needed for successful HF therapy, and targeting the bioenergetic 
deficit through restoration of mitochondrial abnormalities has recently emerged as a promis-
ing strategy [4].
While LV-centered pathology constitutes the largest number of HF cases, it is ability of the 
right ventricle (RV) to function that predicts survival in many cardiovascular disease contexts 
including pulmonary hypertension [5], (which will be reviewed in much greater detail below), 
heart failure with preserved ejection fraction [6], and dilated cardiomyopathy [7]. However, 
no RV-directed therapies exist, and far less is known about the pathophysiology of the failing 
right heart than the LV. So, while considerable progress has been made to elucidate the meta-
bolic and mitochondrial derangements that underlie LV failure, basic understanding of mito-
chondrial and metabolic derangements in RV dysfunction continues to be ill-defined. Here, 
we will present what is known about RV failure and the role of mitochondria and metabolism 
in models of experimental RV failure and in human populations with right HF. We believe 
successful HF therapies must target the failing RV for significant improvement in clinical and 
therapeutic outcomes.
2. The healthy right and left ventricles
Although many similarities exist between the ventricles, and they work in concerted effort to 
efficiently contract and relax for sufficient blood delivery, important embryological, physi-
ological, and pathophysiological differences exist between the right and left ventricles [8]. 
We will briefly discuss a few of these differences, with a specific focus on mitochondria and 
metabolism.
2.1. Embryology, anatomy, and physiology
The RV and LV have different embryological origins and diverge early in development. The 
RV derives from the anterior (secondary) heart field, while the LV derives from the early heart 
tube (primary heart field) [9]. This early divergence is transcriptionally regulated, and several 
transcription factors have been identified which are responsible for the chamber-specific devel-
opment including Hand2 and Tbx20 [10]. During gestation, the RV functions as the systemic 
pump. After birth, the RV becomes coupled to the low-pressure pulmonary circulation. As the 
ductus arteriosus and foramen ovale close, peripheral vascular resistance (PVR) decreases, 
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leading to an increase in RV compliance, regression of muscle mass, and shifting of the inter-
ventricular septum toward the RV, resulting in a concave shape of the ventricle in adulthood. 
Consequently, right sided pressures are significantly lower than the systemically-coupled left 
sided pressures. Due to its coupling to a low-pressure circuit, the RV is approximately 1/3 
the thickness of the LV. As a result of lower pressures and wall stress, the RV has a lower O
2
 
requirement both at rest and during exercise. Consistent with a lower workload, coronary 
blood flow and O
2
 delivery to the RV are comparatively lower than the LV [11]. At rest, the LV 
extracts 75% of O
2
 and the RV ~50% of the available coronary O
2
. These basal differences in 
oxygen uptake are important under periods of physiological or pathological stress, particu-
larly those in which oxygen availability changes. Further, the ventricles can adapt to changes 
in oxygen availability through different mechanisms, with the RV meeting O
2
 demands by 
either increasing coronary flow or by increased O
2
 extraction [12], whereas the LV primarily 
increases coronary flow to match demand [13]. These data are consistent with the response of 
the ventricles to pathological insult, which will be discussed in greater detail below.
2.2. Mitochondrial function and metabolism in the healthy heart
2.2.1. Cardiac metabolism
In healthy states, the heart derives energy from multiple sources to match the demand of con-
tractile function, and can serve as an energetic omnivore based on substrate availability. When 
given a choice, however, the heart prefers lipid, based on significantly higher ATP produc-
tion per carbon molecule compared to glycolysis. The first report of the heart's preference for 
lipid was published in 1953 [14], with subsequent studies confirming that fatty acids constitute 
60–90% of cardiac ATP sources with carbohydrates supplying the remaining 10–40% [15]. Fatty 
acids are transported into cardiomyocytes through fatty acid transporters and subsequently 
into the mitochondria by carnitine palmitoyltransferase-1 into the matrix where they undergo 
β-oxidation. The successive oxidation of fatty acid chains provides acetyl CoA that enters the 
Kreb's Cycle to produce energy to supply the demand of contraction. Glucose is transported 
into cardiomyocytes by facilitated diffusion mediated by glucose transporters GLUT1 and 
GLUT4 (insulin-dependent). Once inside the cell, glucose is phosphorylated by hexokinase 
as the first step in glycolysis. Nine steps later, pyruvate is either decarboxylated by pyruvate 
dehydrogenase (PDH) to form acetyl CoA to be transported into the mitochondria to begin 
Kreb's Cycle, or reduced to form lactate and subsequent anaerobic metabolism.
Assuming similar metabolism and mechanisms of control of these pathways between the 
ventricles might be overly simplistic. As discussed above, the RV is thinner and has a different 
shape than the LV, which contributes to differential responses to pathological load (discussed 
below). Transcriptional profiles, including those which regulate metabolism, differ between 
ventricles, as a comparative gene expression of mRNA and microRNA between control RV 
and LV samples identified numerous genes with differential expression between the ven-
tricles [16]. These genes spanned a wide variety of biological processes including metabolism, 
with carbohydrate metabolism (three differentially expressed genes), lipid, fatty acid and ste-
roid metabolism (11 genes), nucleic acid (30 genes) and protein metabolism (22 genes), as well 
as other metabolic genes (11 genes) significantly varying between ventricles [16].
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2.2.2. Mitochondrial content, dynamics, and function
The heart is an extremely energetically active organ. Despite accounting for less than 1% of 
body weight, it consumes roughly 8% of total ATP [4]. The process of energy production and 
consumption is incredibly dynamic, as the heart only stores enough energy to supply a few 
beats and turns over the entire metabolite pool every 10 seconds [17]. To meet this costly energy 
demand, the heart is the most mitochondrially-dense tissue, with mitochondria comprising 
25–30% of cardiac myocyte cell volume [18]. Mitochondria are responsible for the majority of 
ATP production in the healthy heart, with some estimates suggesting that close to 95% of cardiac 
ATP production occurs through mitochondrial oxidative phosphorylation [19]. Mitochondria 
are double membrane-bound organelles which are tightly regulated within the myocardium to 
facilitate efficient energy production. ATP is produced through oxidation of metabolic fuel to 
provide reducing equivalents (NADH and FADH
2
) that are coordinately used to generate a pro-
ton motive force across the inner mitochondrial membrane to drive ATP synthesis. Successive 
electron transfer through complexes I through IV of the electron transport chain culminates in 
ATP synthesis through complex V (ATP Synthase) in an oxygen-dependent manner.
It has been recognized for quite some time that mitochondria exist in a dynamic reticulum 
and not as isolate organelles [20]. This network not only allows for efficient ATP production, 
but also facilitates mitochondrial quality control. The maintenance of this network occurs 
through continuous mitochondrial fusion and fission, a process mediated by both inner and 
outer mitochondrial membrane proteins. Fusion, the elongation of the mitochondrial network, 
increases mitochondrial mass and is regulated mainly by mitofusin-1 and mitofusin-2 (Mfn1 
and Mfn2) of the outer mitochondrial membrane and optic atrophy-1 (Opa1) of the inner 
membrane. Fission, the fragmentation of the mitochondrial network, results in a greater num-
ber of smaller mitochondria, and is mediated in part by dynamin-related protein-1 (DRP-1) 
and fission protein 1 homolog (Fis1) [21]. Fusion and fission are critically necessary for car-
diac development as loss of any of these proteins is embryonically lethal [22–24]. Substantial 
evidence suggests they are also important in the adult heart, as genetic manipulation of these 
proteins has profound impact on cardiac function.
In addition to regulating mitochondrial shape and size, mitochondrial fission and fusion pro-
teins also regulate mitochondrial quality control through mediating mitophagy, the cellular 
process of removing damaged mitochondria through autophagy [25]. Autophagy, a highly con-
served lysosomal-dependent process of removing damaged cargo and recycling long-lived pro-
teins and organelles, plays a pivotal role in a number of disease states, including cardiovascular 
diseases [26]. Though the exact mechanisms of mitophagy are far from resolved, it is generally 
believed that too much mitophagy results in cardiomyocyte death and can contribute to cardiac 
dysfunction [27] while too little may impair the removal of damaged mitochondria, causing the 
accumulation of damaged mitochondria which lose mitochondrial membrane potential, pro-
duce excess reactive oxygen species, and impart cellular damage [28]. Microtubule associated 
protein light chain 3 (LC3) is often used as a marker of autophagy; LC3-I (the cytosolic isoform) 
is converted to LC3-II during the formation of autophagosomes. Additional mitochondrial spe-
cific regulators of this process include PINK1 and Parkin [28]. In addition to these protein mark-
ers of mitophagy, the process can also be visualized by electron microscopy (EM).
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In addition to dynamically undergoing fission and fusion to regulate the mitochondrial net-
work, mitochondrial turnover or biogenesis, creates new mitochondria. Mitochondria have 
their own DNA (mtDNA) and genetic code that is distinct from nuclear genetics. The bio-
genesis of mitochondria is a cooperative effort between mitochondrial and nuclear-encoded 
genes to synthesize all proteins which comprise the five electron transport chain complexes. 
Biogenesis is transcriptionally regulated by peroxisome proliferator-activated receptor-gamma 
coactivator 1-α (PGC-1α), the “master regulator” of biogenesis [29], transcription factor of mito-
chondria (TFAM), and nuclear respiratory factor 1 (NRF1) [30]. Biogenesis of mitochondria 
also requires the synthesis of cardiolipin, a mitochondrial-specific phospholipid located on the 
inner mitochondrial membrane which regulates respiratory enzyme super complex assembly 
[31]. The transcriptional assessments of TFAM, PGC-1α and NRF1 or markers of mitochondrial 
content are often used as surrogates of biogenesis, a cumulative process which is truly repre-
sented by net synthesis of mitochondrial proteins and/or lipids into functioning organelles [32].
Mitochondrial biology and physiology are further complicated when we consider the arrange-
ment of mitochondrial populations within the adult heart. Three distinct cardiac populations 
have been identified: the subsarcolemmal mitochondria (SSM), located along the perimeter 
of the cell, interfibrillar mitochondria (IFM), located between the myofibrils [33], and peri-
nuclear mitochondria which are arranged in clusters surrounding nuclei and are presumably 
involved with transcriptional activity. Although never directly tested, SSM are hypothesized 
to provide ATP for basic cell functions, whereas IFM provide energy for the contractile appa-
ratus. The original description of IFM and SSM populations identified differences in biochem-
ical and respiratory properties, as well as ultrastructural differences [33]. Following years of 
debate as to whether these two populations were different and discrepancy over the causal 
role of isolation procedures in obscuring differences, consensus seems to have been reached 
regarding important physiological differences in IFM and SSM. It should be noted that these 
differences have only been identified in LV mitochondria, and to our knowledge, subpopula-
tions of SSM and IFM have never been described in the RV.
Indeed, most of what we know about mitochondrial structure and function in the healthy heart 
derives from studies of the LV, and only a few studies have compared healthy right and left ven-
tricles. However, a small report suggests differential expression of autophagy and mitophagy 
regulators in the RV compared to LV [34]. A proteomic analysis of healthy rabbit and porcine LV 
and RV free walls demonstrated similar cellular aerobic capacity, mitochondrial volume, mito-
chondrial electron transport chain content (complexes I, III, IV, and V), as well as mitochondrial 
enzyme activity [35]. Our group assessed mitochondrial content and electron transport chain 
activity, as well as protein markers of mitochondrial dynamics in the RV and LV from healthy 
2-week old cows (Figure 1). While we generally found similar mitochondrial profiles between 
the ventricles, there were some subtle differences including higher relative copy number of COXI 
(mt/nDNA) and higher expression of Mfn1 in the RV compared to the LV. Together, the few 
published papers comparing the LV and RV and the data from our group suggest that though 
small or subtle, differences exist in mitochondrial physiology in the RV and LV, consistent with 
the different energetic and functional capacities of the ventricles. A more careful description of 
interventricular differences will aid in understanding pathological adaptations that occur within 
these organelles, and the contribution they play in development of cardiac disease.
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2.2.3. Non-energy producing roles for mitochondria in the healthy heart
Mitochondria are a major source of cardiac reactive oxygen species (ROS), and the largest pro-
ducer of ROS within the cell [36]. Several labs have identified superoxide (O
2
•−) as the primary 
mitochondrial source of ROS. Superoxide formation occurs on the outer mitochondrial mem-
brane, in the matrix, and on both sides of the inner membrane. The relative contribution of 
each site to total O
2
•− varies from tissue to tissue and depends on respiration state of the mito-
chondria. In heart mitochondria, complex III appears to be most responsible for O
2
•− forma-
tion [37]. When mitochondria are functioning normally, ROS production is low. Although a 
physiological amount of ROS are produced for oxidant-sensitive cell signaling, these ROS are 
balanced by both mitochondrial and cytosolic scavenging systems to prevent oxidative dam-
age. The matrix contains a specific form of superoxide dismutase (SOD) with manganese in 
the active site (MnSOD, or SOD2) [38]. SOD2 dismutates O
2
•− into hydrogen peroxide (H
2
O
2
), 
which is catalyzed to water and molecular oxygen by catalase, a major detoxifying enzyme 
present in heart mitochondria [39]. In addition to these enzymes, other enzymes including 
glutathione peroxidases, as well as non-enzymatic molecules like vitamins C and E, help to 
attenuate excess ROS production. However, if ROS production exceeds the ability to remove 
them, oxidant damage occurs in the form of lipid peroxidation (including oxidation of both 
inner and outer membranes, and cardiolipin), mitochondrial protein oxidation, and oxidant 
damage to mtDNA.
Figure 1. Mitochondrial content, dynamics, and activity in healthy right ventricle (RV) and left ventricle (LV) from 
neonatal cows. (A) Representative electron micrographs of the mid-RV and LV of control cows. (B) Expression of 
electron transport chain complexes does not differ in the healthy ventricles. OXPHOS complex expression was assessed 
by immunoblotting using an antibody against one subunit of each complex. (C) Representative image. (D) Mitochondrial 
content, as assessed by mt/nDNA copy number, is slightly different between ventricles, as COX1 copy number is higher 
in the RV than the LV. (E) Mitofusin-1 (Mfn1) expression is significantly higher in the RV than the LV, with no differences 
in other mitochondrial dynamics markers. (F) Complex I and V activity do not differ between healthy RV and LV, 
as assessed by spectrophotometric assay. All comparisons were assessed by Student’s t-test. *p < 0.05, n = 10 in each 
ventricle. White bars: RV; black bars: LV. Adapted from Bruns, DR et al. AJP-lung, 2014.
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In addition to damaging macromolecules, excess ROS can trigger apoptosis. The observation 
that mitochondria trigger cardiomyocyte apoptosis was first described in 1999 [40]. This study 
demonstrated that when cardiomyocytes are exposed to hydrogen peroxide, Bad, a pro-apop-
totic family member of Bcl-2 family, translocates to the mitochondria, resulting in the release of 
cytochrome c into cytoplasm which leads to the activation of caspase 3 and programmed cell 
death. Furthermore, both pro-apoptotic proteins Bax and Bak co-localize with Mfn2 on the outer 
mitochondrial membrane [41]. Drp1 is also recruited by Bax in response to apoptotic stimuli, and 
colocalizes with Bax at the outer mitochondrial membrane [41]. Conversely, OPA1 is strongly 
anti-apoptotic by preventing cytochrome c release independent from modulation of fusion [42]. 
Taken together, these findings suggest that in addition to their roles as primary energy produc-
ers, the mitochondria are key contributors to redox homeostasis and regulation of programmed 
cell death, both of which contribute to healthy and pathological cardiac function.
While little is known regarding basal differences in ROS production, antioxidant defenses, and 
apoptotic signaling between the healthy LV and RV, two recent studies suggest differences may 
exist between the ventricles in healthy hearts and in response to cardiac stress. Schreckenberg and 
colleagues [43] used a model of systemic nitric oxide (NO) depletion in rats by administration of 
the pharmacological nitric oxide synthase inhibitor L-NAME. They evaluated cardiac antioxi-
dant capacity in response to L-NAME and in a control (untreated) group. Chronic NO deficiency 
is associated with oxidant stress, however it appears to do so in a ventricle-specific manner. 
Dihydroethidium staining, used to detect ROS, showed elevated free radical load in untreated 
RV control samples compared with the LV, as well as elevated peroxynitrite, both of which were 
further increased during L-NAME treatment. To identify mechanisms underlying the differential 
formation of ROS in the LV and RV, the authors examined expression of antioxidant enzymes 
and found that L-NAME treatment induced SOD2 expression in the LV by 51%, but depressed 
SOD2 by 30% in the RV. The authors concluded that while the LV increases SOD2 to compensate 
for increased oxidant load with NO deficiency, the RV does not. Importantly, these biochemical 
differences in redox status were correlated with changes in RV geometry and function indicative 
of cardiac dysfunction. A second small study of ischemia–reperfusion injury in a bi-ventricular 
isolated working heart preparation suggests that mechanisms of myocardial apoptosis also differ 
between the ventricles. While both ventricles saw similar upregulation of apoptosis in response to 
ischemia as assessed by cleaved caspase-3 expression, the RV downregulated anti-apoptotic regu-
lator Bcl, while the LV did not [34]. Though this study was small, and performed no follow-up of 
additional apoptotic regulators or ROS signaling in the healthy heart, it does suggest that differ-
ent mechanisms may underlie the ability of the two ventricles to regulate ROS production, anti-
oxidant defenses, and apoptosis. Together, this work suggests that inherent differences between 
the ventricles with respect to these signaling pathways may be especially relevant in response to 
stresses which promote redox dys-homeostasis including ischemia, reperfusion, and hypoxia.
3. Cardiac remodeling and heart failure
In response to pathological stress, the heart remodels, resulting in changes in structure, 
shape, or physiology of the heart and its cellular components. While remodeling can occur 
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 physiologically such as in response to exercise or pregnancy, pathophysiologic remodeling is 
a maladaptive process that occurs with stress such as myocardial infarction or hypertension 
(chronic pressure overload). Adaptations evidenced at the organ level can occur at the level 
of myocyte, as well as within other cardiac cell types including fibroblasts and endothelial 
cells. Typically, remodeling is not an acute event, but rather occurs as a continuum of changes 
both adaptive and maladaptive, first evidenced by ventricular hypertrophy, dysfunction and 
abnormalities in filling and contraction. In the continued face of stress and/or adverse signal-
ing modalities the heart continues to remodel resulting in overt failure - the inability of the 
heart to supply sufficient circulation for the needs of the body. The response of the RV or LV to 
pathological stress is complex and is likely a cumulation of the nature, severity, and chronic-
ity (acute versus chronic) of the insult. In addition, the timing of the insult (newborn, juvenile, 
adult, or aged) likely has a large impact on cardiac remodeling. Insults that are initiated early 
in life tend to be better tolerated than those in adulthood [44]. Though cardiac aging research 
and RV aging are understudied, the aged heart has been suggested to perform even poorer in 
response to pathological stress, an area which warrants future research efforts.
It should come as no surprise given the physiological differences between ventricles, that the 
ability to adapt to pathological load greatly varies between the left and right heart. While it is 
generally accepted that the RV is able to tolerate volume overload well [45], it poorly tolerates 
pressure overload (afterload). Experimentally, an increase in pulmonary artery pressure of 
20 mmHg compared to a similar increase in systolic afterload resulted in a 30% decline in RV 
stroke volume, compared to only a 10% reduction in LV stroke volume [46]. Mechanistically, 
the thin wall of the RV along with reduced elastance is thought to reflect this poor tolerance 
for increases in afterload. This observation is clinically highly relevant, as patients with sys-
temic hypertension compensate for the increased load for many years before diagnosis or 
treatment of cardiac disease, but patients with pulmonary hypertension (PH, which will be 
discussed in greater detail below), often rapidly progress to right heart failure.
3.1. Right heart failure
Right heart failure (RHF) is a syndrome reflecting the inability of the RV to fill or eject prop-
erly. Clinically, it manifests as fluid retention (peripheral edema) and decreased systolic 
reserve or cardiac output, which often presents as exercise intolerance [47]. In the case of RV 
geometry, the ventricle becomes more concentric, and the interventricular septum flattens. 
In humans, right heart failure is diagnosed through a combination of clinical findings, labo-
ratory tests and imaging. Similarly, in larger animal models of RV failure (below), it can be 
measured by echocardiography, whereas in mouse models it is generally demonstrated by 
morphometric changes including RV/LV ratios and myocyte size.
3.2. Models of right heart failure
Understanding RV failure requires the use of animal models that are primarily or predomi-
nantly right-sided. Therefore, although the most common cause of RV failure in humans is 
left-sided heart failure, it is more helpful to study the RV in diseases and models in which 
it is primary. For reasons including methodological constraints, clinical relevance, and the 
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 sensitivity of the RV to increased afterload (compared to the insensitivity of the RV to volume 
overload), most groups use models of RV pressure overload. However, we should mention 
that other causes of RV failure include valvular insufficiency, congenital disease including 
tetralogy of fallot, pulmonary atresia, truncus arteriosus, and hypoplastic left heart syn-
drome, RV ischemia/infarct, and amyloid and sarcoid [44]. Below, we'll briefly overview 
common animal models of RV failure and how they recapitulate human disease, which are 
summarized in Table 1.
Pulmonary artery banding (PAB) involves surgical constriction of the pulmonary artery, in 
a manner equivalent to the commonly used transaortic constriction (TAC) model of LV pres-
sure overload. Administration of a band around the pulmonary artery results in pulmonary 
constriction, increased afterload, RV hypertrophy, and eventually failure. While similar meth-
odologically and conceptually to TAC, an RNA-seq experiment comparing the RV and LV in 
isolated TAC or PAB suggests that the two ventricles do not respond in an entirely similar 
manner [48]. Of the nearly 3600 genes identified, only 192 were commonly expressed in both 
ventricles, 565 were unique to the RV, and 327 were unique to the LV. Canonical pathway 
enrichment only revealed oxidative phosphorylation as similar between the two ventricles 
[48]. Therefore, despite being methodologically and conceptually equivalent models of iso-
lated pressure overload, TAC and PAB do not elicit identical molecular signatures, again sug-
gesting that important differences between the ventricles may explain disease trajectory and 
prognosis.
A more clinically relevant model of RV afterload is pulmonary hypertension (PH). The World 
Health Organization classifies five distinct groups of PH based on etiology, prognosis, and ther-
apy. However, they're all linked by an increase in mean pulmonary artery pressure of >25 mmHg 
at rest [49]. The increased pulmonary pressures cause pressure overload in the RV, isolated RV 
Human RHF Experimental RHF
LV failure Pulmonary artery banding (PAB)
Pulmonary hypertension Pulmonary hypertension: chronic hypoxia, MCT, 
SuHx, BMP2R
Congenital disease: hypoplastic left heart syndrome, tetralogy of 
fallot, pulmonary atresia
Not available
Amyloid sarcoid Microbial infection, genetic knockout
RV Ischemia/infarct Right coronary ligation (sheep)
Valvular disease Not available
Legend: LV failure is the most common cause of RHF in humans. Pulmonary hypertension is a heterogenous disease, 
classified into five groups by the World Health Organization, but generally refers to an increase in pulmonary arterial 
pressure, causing increased RV afterload. Congenital diseases, amyloid, sarcoid, RV ischemia and infarct, and valvular 
disease (tricuspid, pulmonic) also contribute to RHF. In experimental RHF, pulmonary artery banding/constriction 
causes an isolated increased RV afterload, similar to transaortic banding in left heart failure. Animal models of PH (rats, 
mice, cows) are also frequently used to cause predominant RHF. MCT: monocrotaline, SuHx: Sugen hypoxia, BMP2R: 
bone morphogenetic peptide receptor models (BMP2R plays a critical role in the pathogenesis of familiar idiopathic PH).
Table 1. Selected causes of clinical right heart failure (RHF) and the corresponding experimental model.
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hypertrophy, dysfunction, and eventual failure. PH can be modeled in animals by different 
approaches including chronic exposure to hypoxia, pharmaceuticals which accelerate pulmo-
nary dysfunction, or their combination. Here, we will briefly discuss the most common labora-
tory approaches to PH, but refer readers to an extensive review of animal models of PH [50].
Exposure to chronic hypoxia while causing systemic reduction in oxygen supply, selectively 
induces pressure overload on the RV. Animal models of chronic hypoxia are often driven 
by normobaric hypoxia, accomplished by nitrogen replacement to reduce partial pressure 
of oxygen, or by hypobaric hypoxia (simulated ~14,000–17,000 feet), reducing overall atmo-
spheric pressure and thus reducing oxygen partial pressure in the inhaled air. Animal models 
of hypoxia-driven PH have been used at least since the early 1960s [51] and can be used to 
elicit predictable and reproducible PH within many animal strains. However, there are some 
unique differences between species worth noting. Bovine models produce robust responses 
to simulated altitude and hypoxia, and were among the most common model used in early 
research [52]. Neonatal calves exposed to chronic hypobaric hypoxia develop severe PH with 
striking remodeling of the pulmonary vasculature [52]. Rodent models of hypoxia are also 
common in the literature, with certain strains of rats developing more severe PH, and mice 
developing the least severe perivascular remodeling [50].
In addition to hypoxia exposure, other models of PH include monocrotaline (MCT) injection, 
a pyrrolizidine alkaloid oxidized in the liver to a bioactive molecule which selectively injures 
the lung vascular endothelium, causing PH [53]. MCT as a model of PH has been in use for 
almost 50 years, and can be produced by a single subcutaneous or intraperitoneal injection of 
the drug. Within hours of injection, pulmonary damage occurs, by 2 weeks PVR has increased, 
and by 3 weeks, increased RV mass is often reported [54]. Some reports also describe liver and 
kidney damage [55], as well as myocarditis of both the RV and LV [56], limiting the use of 
MCT to study isolated RV hypertrophy and failure. A relatively recent model to the PH litera-
ture is a model of severe PH that combines chronic hypoxia plus a pharmaceutical vascular 
endothelial growth factor (VEGF) receptor inhibitor. This model, coined the Sugen hypoxia 
(SuHx) model after the VEGF receptor inhibitor Sugen 5416, has been modified for both mice 
and rats, and is characterized by persistent pulmonary vasculature disease and right heart 
failure [57]. Alternative animal models of PH worth mentioning include bleomycin injury and 
single gene mutations. Bleomycin, an antibiotic, is a common model for pulmonary fibrosis in 
mice. A single intratracheal dose results in PH after 2–5 weeks, a doubling of right ventricular 
systolic pressure, and a drop in cardiac output [58]. Lastly, several human mutations have 
been linked to elevated pulmonary pressures and PH, with the bulk of experimental PH stud-
ies using models with mutations of bone morphogenetic protein receptor type II [59].
4. Molecular mechanisms of left heart failure
All cell types within the heart respond to stress, including in response to chronic pressure over-
load [60]. However, the majority of research has focused on changes within the myocytes as they 
are the primary cell type responsible for contraction and heart failure is a disease of impaired 
cardiac function. The hallmark molecular change of myocyte remodeling is hypertrophy. In 
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response to pathological load such as pressure overload, myocyte size increases via synthesis 
of new sarcomeres. Myocytes also reactivate a fetal program of gene expression, now often 
referred to as the hypertrophic gene program [61]. While initially characterized in the failing 
left heart, the fetal (hypertrophic) gene program has now been shown to also occur in RV failure 
[62]. While believed to be compensatory at first, over time this is maladaptive, and likely contrib-
utes to the energy deficit of the failing heart.
4.1. Metabolic remodeling and mitochondrial dysfunction in left heart failure
Mitochondrial and metabolic abnormalities are well-established in left-sided HF. Since this 
topic will be more extensively covered elsewhere, we will just briefly discuss mitochondrial 
dysfunction and the metabolic switch in the failing left heart. Considerable evidence exists for 
an energetic deficit in HF, both in pre-clinical animal models of disease, and in studies from 
explanted human hearts (reviewed in [4]). One of the hallmarks of the hypertrophied or fail-
ing heart is a metabolic switch [63]. As the heart remodels, it undergoes a switch from fatty 
acid oxidation (FAO) to glycolytic carbohydrate metabolism. Although it is still a matter of 
debate whether this switch is causal, associative or compensatory, it is clear that the energy 
starved heart no longer produces the majority of its ATP from lipid sources. It has been sug-
gested that this switch is designed to allow more efficient energy production with respect 
to oxygen since under states of low oxygen availability carbohydrate metabolism produces 
more ATP per mole of oxygen [64].
Due to their primary role as ATP generators, mitochondrial dysfunction has been mechanisti-
cally linked to the energy starved failing heart. Mitochondrial dysfunction is well described 
in the failing LV across many different pre-clinical models including guinea pigs [65], rats 
[66], rabbits [67], and dogs [68] with dilated, ischemic, and diabetic heart failure. Similarly, 
decreased respiration and respiratory control ratios, associated with an overall loss of oxida-
tive capacity [69], have been observed in human explanted hearts from patients with ischemic 
and dilated cardiomyopathy. In addition to depressed oxidative phosphorylation, mitochon-
drial biogenic signaling is depressed in HF, with PGC-1α downregulated in different models 
of HF [70, 71]. Together, substantial data links mitochondrial respiratory deficits with the fail-
ing LV and suggests interventions aimed at preservation of mitochondrial function may have 
therapeutic potential. Observations of changes in the shape of mitochondria in HF spurred 
the idea that the major proteins regulating mitochondrial dynamic could be causally involved 
in development of the disease [72–74].
As discussed above, ROS production in the healthy heart is countered by enzymatic and non-
enzymatic scavenging of ROS to prevent cellular damage. However, increased ROS and oxi-
dant stress have been reported in many types have cardiovascular disease, including early in 
the development of pressure overload-induced left HF [75]. In addition to damaging cellular 
macromolecules, increased ROS can activate several cell-signaling processes including apop-
tosis and opening of the mitochondrial transition pore (mPTP) which are known to correlate 
with adverse health outcomes. Opening of this pore is associated with oxidant stress and 
mitochondrial dysfunction, and increased opening is observed in HF [75]. Although apopto-
sis of cardiomyocytes is rare in the healthy heart, it is well-established that apoptosis increases 
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in human HF [76]. As adult cardiac myocytes have limited regenerative capacity, the loss of 
these cells is often counteracted by replacement with non-myocytes, promoting fibrosis and 
cardiac dysfunction.
5. Molecular mechanisms of right heart failure
The bulk of the research thus far in the field of RV failure and mitochondrial function has 
focused on PH-associated changes within the pulmonary vasculature (pulmonary artery 
smooth muscle cells, endothelial cells, and fibroblasts [77]) and metabolic changes that under-
lie activated inflammatory cells (reviewed in [78, 79]). In addition, a systemic metabolic and 
mitochondrial hypothesis has been put forward, based on similar changes in mitochondrial 
function observed in skeletal muscle in models of PH [80]. However, a few RV-specific inves-
tigations of changes in metabolism and mitochondrial function exist, and we'll review this 
evidence below.
5.1. Metabolic remodeling in right heart failure
Although the data are less extensive than in the LV, the metabolic switch that occurs during 
LV hypertrophy and dysfunction also occurs in models of RV dysfunction [81, 82]. Several 
groups have reported upregulated glycolysis with suppression of FAO, and associated global 
changes in gene expression favoring glucose oxidation and downregulation of PPARα tar-
get genes [62]. Mechanistically, pyruvate dehydrogenase kinase (PDK) has been linked to 
the metabolic switch. PDK, an inhibitor of pyruvate dehydrogenase, is upregulated in RV 
hypertrophy. This PDK-mediated metabolic switch is associated with decreased RV myocyte 
contractility and cardiac output [81]. The shift to aerobic glycolysis has several consequences 
for the heart. First, greater amounts of lactate are produced, shifting redox status and other 
homeostatic outcomes, and second, fewer ATP molecules/glucose molecule are produced (32 
during glucose oxidation, and 2 during glycolysis). To compensate for increased glycolysis, 
glucose uptake is accelerated, and can be assessed by positron emission tomography, both 
in experimental PH and RV dysfunction [83, 84], and in patients with pulmonary arterial 
hypertension [85].
As in left heart failure, researchers have attempted to explain the metabolic switch based on 
energy production relative to oxygen availability. The pressure overloaded RV is oxygen 
deprived. In the setting of an oxygen limited hypertrophic RV, energy production which favors 
a high ATP/O
2
 ratio would benefit the working heart, and FAO uses 12% more oxygen than 
glucose oxidation to generate the same amount of ATP [86]. Some experimental data support 
this hypothesis, with reports of systolic perfusion gradients limiting coronary artery flow [87], 
coupled with increased metabolic demands in the hypertrophied heart, which result in a local-
ized RV ischemia. However, the question of oxygen supply in RV hypertrophy is insufficiently 
answered. While it may be true that angiogenic potential in the failing RV is attenuated, result-
ing in ischemia [88], methodological difficulties have precluded accurate assessment of RV 
oxygen supply. Further, other groups have argued that reliance on carbohydrate metabolism 
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predisposes the hypertrophied myocardium to contractile dysfunction, and maintaining the 
inherent metabolic profile of fatty acid fuel preference may be a more beneficial approach [89].
5.2. Mitochondrial dysfunction in right heart failure
Similar to the LV, mitochondrial dysfunction is also implicated in RHF, albeit with less litera-
ture supporting the mechanistic link, and more conflicting reports depending on the model. 
MCT and SuHx models of RHF tend to demonstrate more severe mitochondrial dysfunction 
and depression of mitochondrial biogenesis. Decreased PGC-1α expression and a net loss of 
mitochondrial protein and oxidative capacity have been reported in SuHx rats, alongside abnor-
mal mitochondrial shape and size by electron microscopy [90]. On the other hand, changes in 
mitochondrial function in chronic hypoxia models have been particularly discordant and war-
rant further discussion. Chronic hypoxia decreased ATP synthesis and measurements of mito-
chondrial number in a rat model of chronic hypoxia in both ventricles, however, the effect was 
slightly delayed in the right compared to LV [91]. Data from our lab in the neonatal calf model 
of PH-induced RV dysfunction also demonstrated similar changes to mitochondrial function in 
both ventricles, with no additional impact of pressure overload on the RV [92]. In these models 
of PH and RV dysfunction, the hypoxic stimulus is administered systemically using a hypobaric 
chamber. Thus, the LV experiences similar degrees of hypoxia as the RV, yet does not show 
signs of contractile or relaxation deficits until much later in disease progression. It's possible 
that interventricular differences in oxygen supply and demand explain the similar findings in 
both ventricles, and support the need for better mechanistic understanding of the similarities 
and differences in oxygen delivery and metabolism in the RV exposed to pathological load.
Mitochondrial dynamics are not well-described in the failing right heart. However, in a study 
by Marsboom et al., administration of the Drp1 inhibitor Mdivi-1 regressed PH in rodents by 
arresting proliferation of pulmonary artery smooth muscle cells, resulting in improved exercise 
capacity and RV function. Therefore, while not described in the RV, modulation of mitochon-
drial dynamics may be therapeutically viable for right heart failure [93]. Even less has been 
described on the role of mitophagy in the setting of right heart failure. However, one group 
has attempted to elucidate the impact of autophagy on remodeling following PAB. p62 and 
LC3 II/I were both increased in the hypertrophied RV [94]. These data support similar findings 
in MCT-induced RV dysfunction, with increased autophagy signaling and autophagosome 
formation by EM [95]. Expression of these markers temporally increased post MCT injection, 
which the authors suggest indicates a causal role for autophagy during the progression from 
hypertrophy to failure. Future work is needed to elucidate the changes that occur with mito-
chondrial dynamics and mitophagy in the failing right heart, and future investigations should 
test myocyte-specific deletion of Mfn1, Mfn2, and Drp1 in experimental RV failure.
Our understanding of mitochondrial abnormalities in human RV failure is equally as under-
studied. Although availability of human samples is methodologically limiting, the use of pedi-
atric congenital heart explants has shed some light on changes which underlie human RHF. One 
study of RV samples obtained from 31 pediatric patients undergoing cardiac surgery for con-
genital heart disease classified patients based on compensated RV function or failure based on 
echocardiography, right heart catheterization and MRI. Citrate synthase activity was maintained 
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during hypertrophy, but decreased at failure, while mtDNA content progressively decreased 
with worsening clinical disease [96]. In addition, adult RV samples of various etiologies demon-
strate increased mitochondrial membrane potential which positively correlates with the degree 
of hypertrophy [97]. A complete understanding of mitochondrial function in human right heart 
failure is limited by methodological constraints of assessing comprehensive ETC function.
5.3. Non-energy producing mitochondrial mechanisms of right heart failure
Studies of non-energy producing roles of mitochondria are in their infancy in the RV. However, 
some evidence supports a causative role of ROS, as increased lipid peroxidation is observed 
in the RV 6 weeks following MCT injection [98]. NADPH oxidase is significant source of ROS 
in LV hypertrophy, and its expression increases during MCT-induced RV hypertrophy along-
side decreased SOD1 and SOD2 expression [99]. Increased expression of pro-apoptotic pro-
teins Bax and capase-3 have also been noted in the RV after PAB, with concomitant increased 
RV myocyte cell death [100]. Together, the limited investigations of the metabolic and non-
metabolic roles of mitochondria in right heart failure highlight the need for additional work 
to elucidate similarly and differentially regulated pathways in left and right HF.
6. Therapeutic intervention
To date, no RV-directed therapies exist. Right-sided heart failure is typically treated with the 
goal of improving LV function or lowering pulmonary pressures. Extrapolation of LV patho-
physiology and pharmacology to the failing RV has not yet proven fruitful, and in some cases, 
has accelerated disease progression [101]. Interestingly, lowering of pulmonary pressures 
(either by pharmaceutical approaches or by lung transplant) does not consistently improve 
RV function [102], suggesting a cardiac-specific irreversible effect of long-term pressure over-
load, or contribution of circulating systemic factors. Whatever the reason for insufficient 
return of RV function despite reduction in afterload, we and others believe that identification 
of new, or repurposing of old therapies requires an RV-centric approach.
6.1. Metabolic therapeutic interventions
Enhancing glucose oxidation at the expense of FAO as emerged as a therapeutic strategy in RV 
dysfunction, based on the reciprocal relationship between these two energy sources. In large 
part, enhancing glucose oxidation has gained attention as a strategy because of the higher 
ATP production per oxygen molecule provided by carbohydrate compared to lipid sources. 
Partial inhibitors of FAO are approved for a few human cardiovascular indications includ-
ing refractory ischemia [103]. These drugs (trimetazidine) have also been experimentally 
tested in RV dysfunction [86]. Rats with PAB-induced RV dysfunction treated with partial 
FAO inhibitors had elevated RV glucose oxidation alongside increased exercise capacity and 
cardiac output. The beneficial effect of this drug has also been demonstrated in  MCT-induced 
RV dysfunction, where trimetazidine enhanced cardiac mitochondrial function and increased 
oxygen consumption while reducing ROS formation [104].
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The metabolic switch that occurs in the hypertrophied RV is suggested to be mediated in part 
through PDK4 [81]. Dichloroacetate (DCA), a small molecule inhibitor of pyruvate dehydro-
genase, improves glucose oxidation and has reported improvements in RV stroke volume, 
cardiac output, and exercise capacity [81, 105]. It is also associated with restoration of RV mito-
chondrial function and mitochondrial-dependent apoptosis [106]. Though a Phase I clinical 
trial has been completed in subjects with advanced PH (Clinical Trial Identifier NCT01083524), 
study results have not been published, and the therapeutic potential of DCA in human RV 
failure remains unknown. As discussed above, the therapeutic strategy of FAO and improved 
glucose oxidation lacks consensus [89], and in part is predicated on the balance between ATP 
production and oxygen availability. While continued efforts to test metabolic mediators in 
RHF are warranted, a mechanistic understanding of energy production, relative RV ischemia, 
and the molecular regulators of these processes are necessary for development of targeted 
metabolic therapy.
6.2. Mitochondrial therapeutic interventions
The causal role of ROS in cardiac dysfunction led to the early belief that antioxidants would 
attenuate cardiovascular disease. In experimental models, treatments with antioxidants have 
somewhat inconsistently tended to improve cardiac function [107]. However, clinical trials 
have largely failed to show benefit of antioxidants in treatment of chronic disease [108]. In light 
of these disappointing results, many groups have taken fundamentally different approaches 
to improving redox status. Induction of endogenous antioxidants by a phytochemical supple-
ment preserved RV function and prevented RV fibrosis and capillary loss [109], suggesting 
activation of cytoprotective transcription factors may more robustly attenuate oxidant stress 
than traditional vitamin supplements. Other groups use mitochondrially-directed peptides 
to scavenge free radicals. One such peptide, SS31, accumulates more than 1000-fold in mito-
chondria [110]. This peptide prevented LV hypertrophy, fibrosis, and diastolic dysfunction 
[111], and reduced mitochondrial oxidant damage [112]. To date, however, targeted mito-
chondrial peptides have not been tested in models of RV failure.
Interventions which boost mitochondrial function and/or biogenesis have large therapeutic 
potential in many types of cardiovascular disease, including RV failure. Phytochemical com-
pounds which elicit mitochondrial biogenic properties have received attention lately, such 
as resveratrol. Resveratrol, the primary polyphenol in red wine, stimulates mitochondrial 
content, ATP production, and FAO, while inhibiting mitochondrial ROS production in several 
tissue types and disease contexts [113, 114]. In addition, it is currently in testing as a therapy 
for chronic obstructive pulmonary disorder (NCT02245932) and non-ischemic heart failure 
(NCT01914081). Identification of other plant-based or pharmaceutical approaches which 
stimulate the synthesis of new mitochondria to increase energy production while decreasing 
oxidant damage may have profound impact on the failing right heart.
6.3. Exercise as right heart therapy
Exercise-induced cardiac hypertrophy has been known to be cardioprotective for decades [115], 
though the exact mechanisms underlying physiological hypertrophy have remained somewhat 
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elusive. RV-specific adaptations to exercise, however, have lagged, in large part due to clinical con-
cerns. Even in healthy individuals with normal pulmonary vascular function, the hemodynamic 
load on the RV increases with a relatively greater proportion during exercise than LV hemody-
namic load. This disproportionate increase in load is accentuated in patients with PH. Exercise-
induced increases in pulmonary artery pressures may exceed RV contractile reserve, resulting 
in attenuated cardiac output and exercise intolerance. Thus only recently have clinical and pre-
clinical studies begun looking at the cardioprotective role of exercise specifically on the RV.
The primary goal of most of the recent studies of exercise in PH patients was to evaluate 
safety of low-level exercise training and changes in systolic pulmonary artery pressure. A 
recent meta-analysis assessing safety outcomes in low intensity aerobic exercise in the form 
of walking, cycling, and light resistance training found improvement of non-invasive mea-
surements of cardiac performance and exercise capacity, as well as improvement of PH func-
tional class and quality of life [116]. Preclinical studies in rodents with MCT-induced PH 
also support the benefit of aerobic exercise training. Several animal studies show improve-
ment of mean pulmonary arterial pressure, measured by right heart catheterization following 
3–5 weeks of exercise training consisting of 30–60 min of 50–60% maximal aerobic capacity 
[117]. Subsequent work to investigate the timing of exercise for therapeutic benefit in experi-
mental PH induced by MCT found that exercise initiated early, before MCT injection, was 
markedly more successful at improving disease outcomes such as survival, diastolic RV func-
tion, cardiac output and exercise tolerance, although some benefit was also observed in the 
cohort who began exercise training 2 weeks after MCT injection [118].
Though exercise stimulates a multitude of cardioprotective mechanisms, endurance exercise is a 
well-known stimulator of mitochondrial biogenesis, first reported by measuring mitochondrial 
mass in the myocardium in 1967 [119]. Subsequent mechanistic studies have shown lower mPTP 
opening rates and apoptosis resistance in endurance trained animals [120], decreased mitochon-
drial ROS production in exercise trained rats [121], and increased oxidative capacity and mito-
chondrial volume [122], and increased mitochondrial biogenesis [123]. To our knowledge, no 
groups have investigated these mechanisms in RV failure and exercise, and virtually nothing is 
known about the molecular adaptations within the RV that occur in response to exercise therapy.
7. Conclusions and future investigations
Understanding of RV metabolism and mitochondrial function has lagged that of the left heart, 
and arguably even less is known about how RV mitochondria adapt to pathological stress. 
What little is known about the role of mitochondrial function and metabolism in the dysfunc-
tional or failing RV (summarized in Table 2) has largely been extrapolated from studies of LV 
dysfunction, and there is a large need for more mechanistic studies of the failing RV to more 
successfully target therapies. In addition to a need for both pre-clinical and clinical investiga-
tions of the right heart, a reductionist approach may be needed to make significant strides in 
RV therapy. The heart (and the RV) is comprised of multiple different cell types. Due to the 
fact that cardiac myocytes are the work horses of the heart, heart failure studies have histori-
cally been myocyte-centric. However, emerging data from our group and others suggests that 
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other cell types within the heart and within the dysfunctional RV may be causally involved in 
disease progression. Specifically, the cardiac fibroblast is emerging as a vital cell type in regu-
lating cardiac function and pathophysiology [124]. Not only do these cells primarily regulate 
the extracellular matrix (and thus fibrosis, electrical remodeling, and inflammation), but it is 
becoming increasingly apparent that they communicate with other cell types such as myo-
cytes to regulate cardiac function. Virtually nothing is known about RV fibroblast mitochon-
drial metabolism or biology, or how these cell types respond to cardiac stress. In conclusion, 
the RV is not a thinner, lower pressure LV. Significant physiological and pathophysiological 
differences separate the two ventricles, and RV-centric approaches are necessary for the iden-
tification, repurposing, or development of therapies for RHF.
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Mitochondrial phenotype Regulators/assessment LV failure RV failure
Content: % of cell occupied by 
mitochondria
mt/nDNA, EM, citrate synthase activity ↓ [68, 71, 77] ↓ [98, 99, 104]
Function: electron transport chain 
activity
Complex I-V activity respiration 
(Ouroboros, Seahorse)
↓ [68–75] NC [98–100, 112]
Fusion: elongation of 
mitochondrial network
Mfn1, Mfn2, OPA1 mitochondrial 
volume
↓ [21, 68] NC [99, 100]
Fission: fragmentation of 
mitochondrial network
Fis1, Drp1 mitochondrial size ↑ [21, 79] ↑ [99–101]
Biogenesis: turnover and synthesis 
of new mitochondria
PGC-1α, NRF1, TFAM mitochondrial 
protein synthesis
↓ [76, 77] NC [98, 104]
Mitophagy: removal of damaged 
mitochondria
LC3 II/I, Pink/Parkin, EM NC [28, 80, 81] NC [102, 103]
Apoptosis Pro: Bax, caspase 3 Anti: Bcl-2 ↑ [34, 69, 70, 84] ↑ [34, 108, 114]
ROS and oxidant damage Protein, lipid, DNA oxidation, ROS 
production (O
2
•−, H
2
O
2
)
↑ [68–70, 74, 82] ↑ [106, 107]
Antioxidant defenses Antioxidant enzyme expression 
(SOD2, catalase) and non-enzymatic 
antioxidants
↓ [68] ↓ [43, 106, 117]
Legend: Mitochondrial alterations in left and right heart failure. Assessment of mitochondrial content, function, 
dynamics, biogenesis, quality control, and non-energy production roles of mitochondria and changes in HF are 
summarized. Arrows indicate directional change with heart failure. NC: no consensus.
Table 2. Mitochondrial changes in left and right HF.
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